Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
17
7
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Our study aimed to assess the impact of pharmacogenomic panel testing in people with HIV (PWH). Prospective, observational intervention assessment. One hundred PWH were provided a comprehensive pharmacogenomic panel during routine care visits within the HIV specialty clinic of a large academic medical center. The panel determined the presence of specific genetic variants that could predict response or toxicity to commonly prescribed antiretroviral therapy (ART) and non-ART medications. An HIV specialty pharmacist reviewed the results with participants and the care team. The pharmacist (1) recommended clinically actionable interventions based on the participants' current drug therapy, (2) assessed for genetic explanations for prior medication failures, adverse effects, or intolerances, and (3) advised on potential future clinically actionable care interventions based on individual genetic phenotypes. Ninety-six participants (median age 53 years, 74% white, 84% men, 89% viral load <50 copies/ml) completed panel testing, yielding 682 clinically relevant pharmacogenomic results (133 major, 549 mild-moderate). Ninety participants (89 on ART) completed follow-up visits with 65 (72%) receiving clinical recommendations based on current medication profiles. Of the 105 clinical recommendations, 70% advised additional monitoring for efficacy or toxicity, and 10% advised alteration of drug therapy. Panel results offered explanation for prior ART inefficacy in one participant and ART intolerance in 29%. Genetic explanation for non-ART toxicity was seen in 21% of participants, with genetic contributors to inefficacy of non-ART therapy identified in 39% of participants. Preliminary data in a small cohort of PWH demonstrates benefit of routine pharmacogenomic panel testing.
Identifiants
pubmed: 37199600
doi: 10.1097/QAD.0000000000003598
pii: 00002030-202308010-00005
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1525-1533Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics . Science 1999; 286:487–491.
Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing . Clin Pharmacol Ther 2016; 99:363–369.
Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update . Clin Pharmacol Ther 2014; 95:499–500.
Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and efavirenz-containing antiretroviral therapy . Clin Pharmacol Ther 2019; 106:726–733.
Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and tamoxifen therapy . Clin Pharmacol Ther 2018; 103:770–777.
Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors . Clin Pharmacol Ther 2015; 98:127–134.
Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, et al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes . PLoS One 2014; 9:e86919.
Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good . Hum Genomics 2019; 13:39.
Tafazoli A, Guggilla RK, Kamel-Koleti Z, Miltyk W. Strategies to improve the clinical outcomes for direct-to-consumer pharmacogenomic tests . Genes (Basel) 2021; 12:361.
Lu M, Lewis CM, Traylor M. Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe . BMC Med Genomics 2017; 10:47.
Gammal RS, Mayes J, Caudle KE. Ready or not, here it comes: direct-to-consumer pharmacogenomic testing and its implications for community pharmacists . J Am Pharm Assoc (2003) 2019; 59:646–650.
Filipski KK, Murphy JD, Helzlsouer KJ. Updating the landscape of direct-to-consumer pharmacogenomic testing . Pharmgenomics Pers Med 2017; 10:229–232.
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgun KM, Gibert CL, et al. VACS Project Team. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals . AIDS 2018; 32:739–749.
Bank PCD, Swen JJ, Schaap RD, Klootwijk DB, Baak-Pablo R, Guchelaar HJ. A pilot study of the implementation of pharmacogenomic pharmacist initiated preemptive testing in primary care . Eur J Hum Genet 2019; 27:1532–1541.
Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade . J Mol Diagn 2016; 18:438–445.
Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing . Clin Pharmacol Ther 2014; 95:423–431.
Wang L, Scherer S, Bielinski S, Muzny D, Jones L, Black J, et al. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: the Mayo-Baylor 10K study . Genet Med 2022; 24:10.
Matey ET, Ragan AK, Oyen LJ, Vitek CR, Aoudia SL, Ragab AK, et al. Nine-gene pharmacogenomics profile service: the Mayo Clinic experience . Pharmacogenomics J 2022; 22:69–74.
Crosslin DR, Robertson PD, Carrell DS, Gordon AS, Hanna DS, Burt A, et al. Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network . Genome Med 2015; 7:67.
Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support . Am J Health Syst Pharm 2016; 73:1967–1976.
Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis . AIDS Patient Care STDS 2019; 33:93–103.
Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT. the HOPS Investigators. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population . J Gen Intern Med 2013; 28:1302–1310.
Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions . J Antimicrob Chemother 2011; 66:2107–2111.
Chen S, St Jean P, Borland J, Song I, Yeo AJ, Piscitelli S, Rubio JP. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics . Pharmacogenomics 2014; 15:9–16.
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, noninferiority trial . Lancet Infect Dis 2013; 13:927–935.
Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization . Pharmacotherapy 2012; 32:333–339.
Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, et al. CISAI Study group. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir . AIDS 2017; 31:455–457.
de Boer MG, van den Berk GE, van Holten N, Oryszcyn JE, Dorama W, Moha DA, Brinkman K. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice . AIDS 2016; 30:2831–2834.
Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir . J Acquir Immune Defic Syndr 2017; 74:423–431.
Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients . HIV Med 2017; 18:56–63.
Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy . Clin Infect Dis 2020; 70:1267–1274.
Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy . Clin Infect Dis 2020; 71:e471–e477.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf . [Accessed 17 January 2022]
Mukerjee G, Huston A, Kabakchiev B, Piquette-Miller M, van Schaik R, Dorfman R. User considerations in assessing pharmacogenomic tests and their clinical support tools . NPJ Genom Med 2018; 3:26.
Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 years later . Clin Pharmacol Ther 2020; 107:171–175.
Nicholson WT, Formea CM, Matey ET, Wright JA, Giri J, Moyer AM. Considerations when applying pharmacogenomics to your practice . Mayo Clin Proc 2021; 96:218–230.
Graves JA, Zhou Z, Garbett S, Peterson JF. The value of pharmacogenomic information . Economic dimensions of personalized and precision medicine 2018; Chicago:University of Chicago Press, 53–86.
Roden DM, Van Driest SL, Mosley JD, Wells QS, Robinson JR, Denny JC, Peterson JF. Benefit of preemptive pharmacogenetic information on clinical outcome . Clin Pharmacol Ther 2018; 103:787–794.
Cummins NW, Badley AD, Kasten MJ, Sampath R, Temesgen Z, Whitaker JA, et al. Twenty years of human immunodeficiency virus care at the Mayo Clinic: past, present and future . World J Virol 2016; 5:63–67.
Bain KT, Schwartz EJ, Knowlton OV, Knowlton CH, Turgeon J. Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE) . J Am Pharm Assoc (2003) 2018; 58:281.e1–289.e1.
Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics . Pharmacotherapy 2014; 34:1102–1112.
Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service . Pharmacotherapy 2013; 33:1156–1164.
Myers MF. Healthcare providers and direct-to-consumer access and advertising of genetic testing in the United States . Genome Med 2011; 3:81.
Tafazoli A, Guchelaar HJ, Miltyk W, Kretowski AJ, Swen JJ. Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice . Front Pharmacol 2021; 12:693453.
Kim K, Magness JW, Nelson R, Baron V, Brixner DI. Clinical utility of pharmacogenetic testing and a clinical decision support tool to enhance the identification of drug therapy problems through medication therapy management in polypharmacy patients . J Manag Care Spec Pharm 2018; 24:1250–1259.